Current and future treatments for peanut allergy.

Area of Science:

• Allergy and Immunology
• Pediatric Medicine
• Pharmacology

Background:

• Peanut allergy (PA) is a prevalent and challenging childhood condition often persisting into adulthood.
• Historically, effective treatments for PA were unavailable, significantly impacting patients' quality of life.
• Recent advancements are transforming the therapeutic landscape for peanut allergy.

Purpose of the Study:

• To review the current and emerging therapeutic interventions for peanut allergy (PA).
• To discuss the growing role and evidence supporting peanut oral immunotherapy (POIT), including FDA-approved options.
• To explore alternative immunotherapy approaches and biologic agents in development for PA.

Main Methods:

• Review of current literature on peanut allergy treatments.
• Analysis of clinical evidence for peanut oral immunotherapy (POIT) and other immunotherapies.
• Examination of data on biologic agents, such as Omalizumab, in PA management.

Main Results:

• Peanut oral immunotherapy (POIT) is increasingly accepted, particularly in preschoolers, demonstrating safety and feasibility.
• Several alternative immunotherapy methods (epicutaneous, sublingual, subcutaneous, intralymphatic) are under investigation.
• Biologic therapies, including Omalizumab, show promise as adjunctive treatments or monotherapy for PA.

Conclusions:

• The treatment paradigm for peanut allergy is shifting towards active interventions.
• Allergists must engage in shared decision-making, considering patient goals and evaluating risks/benefits of diverse therapies.
• A future with multiple therapeutic choices for PA necessitates informed clinical judgment.